AmaStella has joined the APT fleet on multiple itineraries.

The latest addition to the APT river cruising fleet has set sail from Amsterdam bound for Budapest, with the MS AmaStella specifically equipped for groups and multi-generational families travelling together.

The 158-passenger vessel is a new flagship of sorts for the line, launching a multitude of new stateroom types including some of the only interconnected staterooms in the river cruise industry. Six pairs of inter-connecting staterooms aim to provide families of up to five with the ability to be housed next door to each other.

At the same time, families of three and four have access to 12 new staterooms designed for triple-share accommodation, while four new suites can welcome four guests across two double beds. Along with its family focus, the new vessel retains APT’s signature destination inspired interiors and layouts with popular features seen on its sister ships such as a heated pool and swim up bar on the top deck, while the popular spa and salon has been relocated down one deck in order to maximise available space.

Guests will also see an increase in the number of panoramic balcony staterooms, affording more with uninterrupted views of European landscapes as the ship sails past. AmaStella also includes in cabin on-demand entertainment and free internet across all stateroom and suite categories as a signature standard. Staterooms also offer complimentary bottled water in the room, replenished daily, while unlimited beer, wine and soft drinks are served with lunch and dinner each day.

AmaStella is now sailing on a number of itineraries including ‘Tulip Time’, ‘Romantic Danube’, ‘Melodies of the Danube’ and some Christmas Markets cruises. The vessel is the first of two new river ships coming for APT this year, with the MS AmaViola joining the fleet next month.

MS AmaStella will offer access to sights such as the Dutch windmills.
The iconic windmills of the Netherlands are among those to be seen in Amsterdam from the new MS AmaStella.

3 COMMENTS

LEAVE A REPLY